IGFBP2 and chronic kidney disease: Except for sST2, all of the investigated biomarkers showed significantly elevated plasma concentrations in the advanced stages of CKD (GDF-15: 3.6-fold increase, H-FABP: 4.4-fold increase, IGF-BP2: 3.0-fold increase, suPAR 2.0-fold increase when eGFR was <30 mL/min/1.73 m2 BSA compared to eGFR ≥ 90 mL/min/1.73 m2 BSA, see Figure 1 and Supplementary Materials, Table A1 in Appendix A).